An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

Nature Biotechnology

Volumn 16, Issue 5, 1998, Pages 444-448

  Chase, Maureen ^a   Chung, Richard Y ^a   Antonio Chiocca, E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Gene therapy; Herpes simplex virus type 1; Prodrug activation

Indexed keywords

CYCLOPHOSPHAMIDE; IFOSFAMIDE; ONCOLYTIC VIRUS; PRODRUG; RIBONUCLEOTIDE REDUCTASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; DRUG ACTIVATION; GENE THERAPY; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; VIRUS MUTANT; VIRUS RECOMBINANT;

EID: 0031947191     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0598-444     Document Type: Article

References (38)

1. Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L., and Coen, D.M. 1991. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-856.
2. Mineta, T., Rabkin, S.D., Yazaki. T., Hunter, W.D., and Martuza, R.L 1995. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Wat. Med. 1:938-943.
3. Boviatsis, E.J., Park, J.S., Sena-Esteves, M., Kramm, C., Chase, M., Efird, J. et al. 1994. Long-term survival of rats harboring brain tumors treated with ganciclovir and a herpes simplex virus vector that maintains an intact thymidine kinase gene. Cancer Res. 54:5745-5751.
4. Chambers, R., Giliespie, G.Y., Soroceanu, l_, Andreasky, S., Chatterjee, J., Chou, J. et al. 1995. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a seid mouse model of human malignant glioma. Proc. Watt Acad. Sci. USA 92:1411-1415.
5. Pyles, R.B., Wamick, RE, Chalk. C.L, Szanti, B.E, and Parysek, U.M. 1997. A novel multiply-mutated HSV-1 strain for the treatment of brain tumors. Hum. Gen. Ther. 8:533-544.
6. Goldstein D. J. and Weller S.K. 1988. Herpes simplex virus type 1 -induced ribonucleotide reductase activity is dispensable for virus growth and DMA synthesis: iso-lation and characterization of an ICP6 lacZ insertion mutant. J. Wol. 62:195-205.
7. Kesari, S., Lee, V.M.Y., Brown, S.M., Trojanowski, J.Q., and Fraser, N.W. 1995. Therapy of experimental brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest. 73:636-648.
8. Lorence, R.M., Reichard, K.W., Katubig, B.B., Reyes, H.M., Phuangsab, A, Mitchell, B.R. et al. 199-1. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J. Natl. Cancer Inst. 86:1228-1233.
9. Bischoff, J.R., Kirn, D.H., Williams, A., Heise, C., Horn, S., Muna, M. et al. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376.
10. Rodriguez, R., Schuur, E.R., Lim, H.Y., Henderson, G.A., Simons, J.W., and Henderson, D.R. 1997. Prostate attenuated replication competent adenovims (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57:2559-2563.
11. Wei, M.X., Tamiya. T., Chase, M., Boviatsis, E.J., Chang, T.K.H., Hochberg, F.H. et al. 1994. Experimental tumor therapy in mice with the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum. Gene Ther. 5:969-978.
12. Chen, L and Waxman, D.J. 1995. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 55:581-589.
13. Moolten, F.L 1994. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1:279-287.
14. Fakhrai, H., Dorigo, O., Shawler, D.L, Un, H., Mercola, D., Black, K.L et al. 1996. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc. Natl. Acad. Sci. USA 93:2909-2914.
15. Roth, J.A., Nguyen, D., Lawrence, D.D., Kemp, B.L., Carrasco, C.H., Person, D.2. et al. 1996. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2:985-991.
16. Moolten, F.L 1986. Tumor chemosensitivity conferred by inserted thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46:5276-5281.
17. Chen, S.H., Shine, H.D., Goodman, J.C., Grossman, R.G., and Woo, S.L.C. 1994. Gene therapy for brain tumors: regression of experimental gliomas by using adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91:3054-3057.
18. Mroz, P.J. and Moolten, F.L. 1993. Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication. Hum. Gene Ther. 4:589-595.
19. Müllen, C.A., Kilstrup, M., and Blaese, R.M. 1992. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. WaH. Acad. Sci. USA 59:33-37.
20. Wei MX, Tamiya, T., Rhee, R.J., Breakefield XO., and Chiocca, EA1995. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with cyclophosphamide/cytochrome P4502B1 gene therapy. Clinical Cancer Research 1:1171-1177.
21. Marais, R., Spooner, R.A., Light, Y, Martin, J., and Springer, C.J. 1996. Genedirected enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56:4735-4742.
22. Chen, L., Waxman, D.J., Chen. D., and Kufe, D.W. 1996. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 56:1331-1340.
23. Clarke, L and Waxman, D J. 1989. OxidaSve metabolism of cyclophosphamide: identification of the hepatic moncoxygenase catalysts of drug activation. Cancer Res. 492344-2350.
24. Sidranski, D., Mikkelsen, T, Schwechleimer, K., Rosenblum, M.L., Cavenee, W.K., and Vogelstein, B. 1992. Clonal expansion ofp53 mutant cells is associated with brain tumour progression. Nature 355:846-847.
25. Bigner, D.D., Bigner, S.H., Ponten, J., Westermark, B., Mahaley, M.S., Ruoslahti, E. et al. 1981. Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J. Neuropathol. Exp. Neurol. 40:201-229.
26. Nilaver, G., Muldoon, LL, Kroll, R A, Pagel, MA, Breakefield, XO., Davidson, B.L et al. 1995. Delivery of herpes virus and adenovirus to nude rat intracerebral tumors following osmotic blood-brain barrier disruption. Proc. Watt Acad. Sci. USA 21 .-9829-9833.
27. Muldoon, LL, Nilaver, G., Kroll, R.A., Pagel, M.A., Breakefield, X.O., Chiocca, E.A. et al. 1995. Comparison of intracerebral inoculation and osmotic bloodbrain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am. J. Pathol. 147:1840-1851.
28. Ram, Z., Culver, K.W., Oshiro, E., Viola, J.J., DeVroom, H.L., Otto, E. et al. 1997. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producer cells. Waf. Med. 3:1354-1361.
29. McCarthy, A., McMahan, L., and Schaffer, P.A. 1989. Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient. J. Wol. 63:18-27.
30. Mineta, T, Rabkin, S.D., and Martuza, R.L 1994. Treatment of malignant glioma using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex virus mutant. CancerP.es. 54:3936-3966.
31. Lukas, J., Petersen, B.O., Holm, K., Bartek, J., and Heiin, K. 1996. Deregulated expression of E2F family members induses S-phase entry and overcomes p16-"-mediated growth suppression. mol. Cell. Biol. 16:1047-1057.
32. Dynlacht, B.D., Flores, O., Less, JA., and Harlow, E. 1994. Differential regulation of E2F trans-activation by cyclin/cdk2 complexes. Genes Dev. 8:1772-1786.
33. DeGregori, J., Kowalik, T., and Nevins, J.R. 1995. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G./S-regulatory genes. Mol. Cell. Biol. 15:4215-4224.
34. Ueki, K., Ono, Y., Henson, J.W., Efird, J.T., von Deimling, A., and Louis, D.N.1996. CKN2/pJ6 or RB alterations occur in the majority of glioblastomas and are inversely correlated. CancerP.es. 56:150-153.
35. VanMeir,EG.,Kikuchi,T.,Tada,M.,lJ,H.,Diserens,A.C.,Wojcik,B.Eetal. 1994.Analysis of thep53 gene and its expression in human glioblastoma cells. Cancer Res. 54:649-652.
36. Carroll, N.M., Chiocca, E.A., and Tanabe, K.K. 1997. The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J. Surg. Res. 69:413-417.
37. Colvin, O.M. 1993. Alkylating agents and platinum compounds, pp. 733-734 in Cancer medicine. Holland, J.F, Frei, E., Bast, R.C. Jr., Kufe, D.W., Morton, D.L., and Weichselbaum, R.R. (eds.). Lea and Fabiger, Philadelphia.
38. Gopferich, A., Alonso, M.J., and Langer, R. 1994. Development and characterization of microencapulated microspheres. Pharm. Res. 11:1568-1574.